<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CC9C7B8A-2A12-43EC-AF3E-9C3B71AC17C3"><gtr:id>CC9C7B8A-2A12-43EC-AF3E-9C3B71AC17C3</gtr:id><gtr:name>Edinburgh &amp; Lothians Health Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2385760-DE2E-4D45-A611-DEB951931E81"><gtr:id>E2385760-DE2E-4D45-A611-DEB951931E81</gtr:id><gtr:name>Scottish National Blood Transfusion Service (SNBTS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:department>School of Medical Sciences</gtr:department><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CC9C7B8A-2A12-43EC-AF3E-9C3B71AC17C3"><gtr:id>CC9C7B8A-2A12-43EC-AF3E-9C3B71AC17C3</gtr:id><gtr:name>Edinburgh &amp; Lothians Health Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2385760-DE2E-4D45-A611-DEB951931E81"><gtr:id>E2385760-DE2E-4D45-A611-DEB951931E81</gtr:id><gtr:name>Scottish National Blood Transfusion Service (SNBTS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CB90AF84-0C45-4AE3-A91A-5F9EDBE89398"><gtr:id>CB90AF84-0C45-4AE3-A91A-5F9EDBE89398</gtr:id><gtr:name>Cell Therapy Catapult</gtr:name><gtr:address><gtr:line1>12th Floor Tower Wing, Guys Hospital, 
Great Maze Pond,</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 9RT</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/02376792-95E4-40A0-972D-D48BA408985E"><gtr:id>02376792-95E4-40A0-972D-D48BA408985E</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:surname>Docherty</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BE22AA55-DA2E-4D89-AEF7-56C1607432A1"><gtr:id>BE22AA55-DA2E-4D89-AEF7-56C1607432A1</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Forbes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1CF5CE78-6A65-449E-A7BD-03E26D7E9824"><gtr:id>1CF5CE78-6A65-449E-A7BD-03E26D7E9824</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Casey</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ015377%2F1"><gtr:id>1E182810-0C62-45FF-9F19-CFD70E0B36A7</gtr:id><gtr:title>Reprogramming of Redundant Human Exocrine Tissue to Endocrine Tissue for Transplantation in the Treatment of Type 1 Diabetes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J015377/1</gtr:grantReference><gtr:abstractText>Type 1 diabetes affects 0.4 to 0.5% of the population and it is one of the commonest long term conditions in children and adolescents. A 70% increase in prevalent cases of type 1 diabetes in those aged under 15 is predicted in Europe between 2005 and 2020. Despite advances in the care of people with type 1 diabetes, the condition continues to be associated with substantial mortality and morbidity with an estimated shortening of lifespan on average of 15 years. Rates of cardiovascular disease are increased 3.6 fold in men and 7.7 fold in women. The avoidance of complications, such as visual loss or end stage renal failure, would be extremely cost effective, but even more importantly would contribute greatly to quality of life. Efforts to reduce such morbidity and mortality associated with type 1 diabetes are hampered by the limitations of current treatments which cannot reflect physiological insulin secretion from intact beta cells. 
Pancreatic islet cell transplantation offers hope for patients with Type 1 Diabetes by replacing the insulin producing tissue and therefore lowering blood sugar levels. The islet isolation laboratory in Edinburgh is a dedicated facility which is staffed 24/7 for human cadaveric islet isolation and has processed over 20 human pancreata in the last 6 months. The clinical programme and isolation facility is fully funded by the Scottish Government and has been set up to provide both a clinical service and to act as a catalyst for islet related stem cell research through links with Edinburgh University, Aberdeen University and the Scottish Centre for Regenerative Medicine. The first transplant was performed in February 2011 with four more in a short period of time. At present multiple donor pancreases are required to treat a single patient as the effectiveness of the initial transplant falls with time and further transplants are required. Only a small fraction of the pancreas has the ability to produce insulin with the remainder producing enzymes, substances which allow the gut to digest food. Using recent research we aim to reprogramme the enzyme producing pancreatic tissue so that instead it produces insulin. Potentially this will allow multiple transplants over a period of years from a single pancreas reducing the requirement for more than one donor.</gtr:abstractText><gtr:technicalSummary>Transplantation of isolated islets of Langerhans is viewed as the only effective treatment for type 1 diabetes that will normalise blood glucose levels without the attendant risk of hypoglycaemic. However, a major problem with current transplantation protocols is that up to three donor pancreases are required for each recipient, and in many cases the function of the graft deteriorates over time. During the isolation procedure, the bulk of the pancreatic material, i.e. the exocrine tissue is discarded. In our preliminary studies we have shown that the exocrine enriched tissue can be reprogrammed using 4 transcription factors (Pdx1, MafA, Ngn3 and Pax4) in combination with 3 growth factors (Betacellulin, Exendin-4 and nicotinamide) and that the efficiency (and direction) of reprogramming is enhanced by inducing the cultured exocrine cells to undergo a mesenchymal to epithelial transition (MET). Our preliminary studies provide proof of concept that we can efficiently reprogramme the exocrine enriched cells of the pancreas. We now propose to take the next step towards developing a novel cell therapy by characterising the cells in detail with a view to generating cells with properties as close as possible to that of an adult human islet cell. 
The overall aim is to enhance the production of functional islet tissue. In aim 1 we will optimise the use of growth factors and small molecules. This will be done by ICC and ELISA using insulin and glucagon expression as an end-point. In aim 2 we will optimise further the transcription factor cocktail used in reprogramming. In aim 3 we will characterise in detail the fully reprogrammed cells, using standard in vitro insulin secretion protocols, and in aim 4 we will test the ability of the reprogrammed to reverse the symptoms of diabetes in an animal model.</gtr:technicalSummary><gtr:potentialImpactText>The research proposed is likely to benefit people with type 1 diabetes. There are about 300,000 people with type 1 diabetes in the UK. The disease is treated with multiple daily injections of insulin combined with blood glucose monitoring and sensible dietary advice as per the DAFNE (dose adjustment for normal eating) course promoted by Diabetes UK. The major challenges in treating people with diabetes are preventing the long term complications of the disease and hypoglycaemia. A proportion of people with diabetes have huge problems controlling their disease particularly with respect to excessive daily excursions in blood glucose levels combined with an unawareness of the onset of hypoglycaemia. This is the group of patients that would benefit most from an islet transplant. However, at present the number of donors would provide tissue for &amp;lt;1% of these people. The problem is exacerbated by the requirement for up to three transplants per patient. A further problem is that the graft tends to fail over a period of time. Our project is aimed at addressing this problem of tissue availability and graft failure. Our preliminary data provide proof of principle that we can get regular access to the human material (8 pancreata between February and November 2011) and that we can efficiently reprogramme it into cells that express the major islet hormones, i.e. insulin, glucagon and somatostatin. With a view to taking this work towards the clinic we now need to characterise the cells in detail and improve the levels of insulin (and glucagon) that are expressed. 
The project will also be of benefit to those companies involved in generating a replenishable supply of human Beta cells derived from ES/iPS cells. Our strategy towards identifying the concentration and temporal effects of transcription factors may help inform strategies targeting the differentiation of ES/iPS cells. The identification of growth factors and small molecules that act individually or in combination to reprogramme towards Beta cells would also be of great value to companies working in this area.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-09-02</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>534517</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Edinburgh &amp; Lothians Health Foundation</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IsletCTS</gtr:description><gtr:id>82184606-3F90-421E-BFDB-9871063E90D3</gtr:id><gtr:impact>Cell Therapy Catapult are in the process of funding this collaborative project.</gtr:impact><gtr:outcomeId>544f688d8ae576.73731497-3</gtr:outcomeId><gtr:partnerContribution>SNBTS provide expertise in developing our protocol under GMP compliant conditions. Lothian Health Board and Edinburgh University provide expertise in human islet isolation, transplantation and clinical diabetes. The Cell Therapy Catapult provide project management and expertise in taking our protocol into the clinic.</gtr:partnerContribution><gtr:piContribution>We provide the underlying science aimed at developing a novel cell based therapy for the treatment of diabetes.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish National Blood Transfusion Service (SNBTS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IsletCTS</gtr:description><gtr:id>85CED016-2B12-4D62-A7A5-26DCE89C8DAD</gtr:id><gtr:impact>Cell Therapy Catapult are in the process of funding this collaborative project.</gtr:impact><gtr:outcomeId>544f688d8ae576.73731497-2</gtr:outcomeId><gtr:partnerContribution>SNBTS provide expertise in developing our protocol under GMP compliant conditions. Lothian Health Board and Edinburgh University provide expertise in human islet isolation, transplantation and clinical diabetes. The Cell Therapy Catapult provide project management and expertise in taking our protocol into the clinic.</gtr:partnerContribution><gtr:piContribution>We provide the underlying science aimed at developing a novel cell based therapy for the treatment of diabetes.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Molecular and Clinical Medicine Edinburgh</gtr:department><gtr:description>IsletCTS</gtr:description><gtr:id>E1192FE0-207A-4AA1-89F3-3EAF5AA88D19</gtr:id><gtr:impact>Cell Therapy Catapult are in the process of funding this collaborative project.</gtr:impact><gtr:outcomeId>544f688d8ae576.73731497-4</gtr:outcomeId><gtr:partnerContribution>SNBTS provide expertise in developing our protocol under GMP compliant conditions. Lothian Health Board and Edinburgh University provide expertise in human islet isolation, transplantation and clinical diabetes. The Cell Therapy Catapult provide project management and expertise in taking our protocol into the clinic.</gtr:partnerContribution><gtr:piContribution>We provide the underlying science aimed at developing a novel cell based therapy for the treatment of diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cell Therapy Catapult</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>IsletCTS</gtr:description><gtr:id>151AC834-A4BC-4F65-B03A-39484A3E8D7A</gtr:id><gtr:impact>Cell Therapy Catapult are in the process of funding this collaborative project.</gtr:impact><gtr:outcomeId>544f688d8ae576.73731497-1</gtr:outcomeId><gtr:partnerContribution>SNBTS provide expertise in developing our protocol under GMP compliant conditions. Lothian Health Board and Edinburgh University provide expertise in human islet isolation, transplantation and clinical diabetes. The Cell Therapy Catapult provide project management and expertise in taking our protocol into the clinic.</gtr:partnerContribution><gtr:piContribution>We provide the underlying science aimed at developing a novel cell based therapy for the treatment of diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A53A3EBB-F46D-48C8-B5C0-E1C3AAB299B7</gtr:id><gtr:impact>These lectures are aimed at school children. They are lectures where the first half (around 15 minutes) is given by clinician and the second half is given by a scientist and research in animal models, stem cells etc. is discussed.

The feedback was incredibly positive. This series of lectures was clearly reaching out to patients, school children and health professionals as well as colleagues. A DVD of the lecture was sent to Malawi where it was widely circulated.</gtr:impact><gtr:outcomeId>540490cae420d1.07357733</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Outreach</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>939119EB-54B2-4C43-9DCA-91BE8301D5A6</gtr:id><gtr:impact>The presentation was to the Moray branch of Diabetes UK in Elgin. The event focused on stem cell research and Diabetes for their members (volunteers, those affected by Diabetes and their carers), and involved a short presentation and then questions and answers. 


Raised awareness of advances in diabetes research.</gtr:impact><gtr:outcomeId>54049393485431.06939882</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.eurostemcell.org/hopebeyondhype</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0B669DC9-07B7-4983-8D8A-03D83268471D</gtr:id><gtr:impact>Insulin at 90
Cell Based Therapy for Type 1 Diabetes
Suttie Centre, University of Aberden

Press Coverage</gtr:impact><gtr:outcomeId>ZCqMzmRYukn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Workshop Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>865560EE-C39A-4C40-97DB-3BFDB9818C92</gtr:id><gtr:impact>The objectives were both (1) to encourage more clinical trainees to consider Regenerative Medicine as an area for postgraduate study and research, and (2) to provide key information to frontline clinicians, allowing them to deliver informed advice to patients and carers who enquire about the opportunities this cutting edge research could bring.

The main aim was education: to provide key information to healthcare professionals enabling them to deliver informed advice to patients and carers who enquire about potential stem cell therapies. In support of this, the course has CPD accreditation (11 credits) from the Royal College of Physicians.</gtr:impact><gtr:outcomeId>54048de5199702.16935904</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>183797</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>706C4FA9-DA2A-4F5C-B4DE-5CB7675B300E</gtr:id><gtr:outcomeId>5405893c909638.52197972</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>499158</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J015377/1</gtr:fundingRef><gtr:id>E797137B-07A8-4D6B-A37D-E03483DB70E5</gtr:id><gtr:outcomeId>54058a5ba2fec1.78092731</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>202451</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:fundingRef>13/0004678</gtr:fundingRef><gtr:id>40833EAF-231A-4990-968A-8E662BAFD0FE</gtr:id><gtr:outcomeId>kv9N6cnTHKB</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to methods of producing pancreatic endocrine cells and
uses of the cells obtained using the methods.</gtr:description><gtr:grantRef>MR/J015377/1</gtr:grantRef><gtr:id>95CA0F0A-1860-48B8-8233-C339CC8FECD6</gtr:id><gtr:impact>A consortium (IsletCTS) has been set up to exploit this patent</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>54049533497846.28619246</gtr:outcomeId><gtr:patentId>SMKBP6968556 - 552</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods of obtaining pancreatic endocrine cells</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention provides methods and materials relating to obtaining or expanding
populations of islet cells, and uses of the islet cells obtained by these methods, for
example in the treatment of diabetes.</gtr:description><gtr:grantRef>MR/J015377/1</gtr:grantRef><gtr:id>0FA93E46-FD0F-41E1-A0E1-C57F6E0D1E22</gtr:id><gtr:impact>A consortium (IsletCTS) has been set up to exploit this patent.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>540494c7e29d28.95566913</gtr:outcomeId><gtr:patentId>SMKLP6968549-551</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods of obtaining islet cells</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>The product relates to a replenishable supply of islets from transplantation based on an allogeneic bank of cells generated from pancreatic MSCs.</gtr:description><gtr:id>C9172BCC-EC63-492D-97CD-EAEFD9E50B71</gtr:id><gtr:impact>Establishment of a consortium, IsletCTS aimed at taking this product into clinical trials.</gtr:impact><gtr:outcomeId>5405850f6b1435.16128467</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Stem Cell Therapy for Diabetes</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cell lines in which MSCs derived from pancreatic beta or acinar cells have been genetically tagged with dsRED.</gtr:description><gtr:id>028AA11E-C26F-4A3D-A191-8EF244C32F4A</gtr:id><gtr:impact>Potential impact on ability to patent aspects of our technology.</gtr:impact><gtr:outcomeId>rQfD9K2wzdP</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Lineage traced human pancreatic cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1F05C2B2-65FC-4823-BD18-A8DEBF628FF5</gtr:id><gtr:title>Kr&amp;uuml;ppel-Like Factor 4 Overexpression Initiates a Mesenchymal-to-Epithelial Transition and Redifferentiation of Human Pancreatic Cells following Expansion in Long Term Adherent Culture.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faf11bf3fa3162067c75e15e9be48a9"><gtr:id>6faf11bf3fa3162067c75e15e9be48a9</gtr:id><gtr:otherNames>Muir KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a93e30a37c343.52245765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DD45E74-FEAC-44B0-8688-C6797A5C14F9</gtr:id><gtr:title>Generation of Functional Beta-Like Cells from Human Exocrine Pancreas.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/646a9a796c02025de09dec09736d0d51"><gtr:id>646a9a796c02025de09dec09736d0d51</gtr:id><gtr:otherNames>Lima MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c2b5b79af025.60643012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B308A2C2-4CE0-4F50-97FC-34464CFBECFD</gtr:id><gtr:title>Cell therapy for type 1 diabetes.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faf11bf3fa3162067c75e15e9be48a9"><gtr:id>6faf11bf3fa3162067c75e15e9be48a9</gtr:id><gtr:otherNames>Muir KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>54044c764c1cb1.70600835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45CE23C4-F4F5-459C-ADCC-BE08EADF5CB8</gtr:id><gtr:title>Suppression of epithelial-to-mesenchymal transitioning enhances ex vivo reprogramming of human exocrine pancreatic tissue toward functional insulin-producing ?-like cells.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/646a9a796c02025de09dec09736d0d51"><gtr:id>646a9a796c02025de09dec09736d0d51</gtr:id><gtr:otherNames>Lima MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_23368_28_23610058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C6E7AF7-8ABB-4B3C-B049-7E73CC611CBF</gtr:id><gtr:title>Islet transplantation from a nationally funded UK centre reaches socially deprived groups and improves metabolic outcomes.</gtr:title><gtr:parentPublicationTitle>Diabetologia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d4317d8bceff2587c17644c5586864a"><gtr:id>8d4317d8bceff2587c17644c5586864a</gtr:id><gtr:otherNames>Forbes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0012-186X</gtr:issn><gtr:outcomeId>56de987497dca6.05930527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C57E9D92-1815-4F6E-B0EF-80873B1C94FE</gtr:id><gtr:title>A comparison of in vitro nucleosome positioning mapped with chicken, frog and a variety of yeast core histones.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c18dc7ef63a55ac30970f21e8b402e4e"><gtr:id>c18dc7ef63a55ac30970f21e8b402e4e</gtr:id><gtr:otherNames>Allan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>pm_23368_28_23871836</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J015377/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>